期刊文献+

糖类抗原15-3检测对乳腺癌骨转移的诊断价值 被引量:2

Determinant of carbohydrate antigen 15-3 for the diagnostic evaluation of bone metastasis of breast cancer
下载PDF
导出
摘要 目的探讨糖类抗原15-3(CA15-3)在评价乳腺癌骨转移的价值。方法纳入在我院接受手术经病理学确诊的86例乳腺癌患者。采用99mTc-MDP核素骨显像检查并进一步病理学确认患者是否发生骨转移,记录发生骨转移的部位和数目。根据是否发生骨转移将患者分为2组。采用化学发光法检测所有患者血清CA15-3水平,比较2组患者CA15-3水平,分析CA15-3水平与骨转移累及部位数目的相关性;采用ROC曲线分析CA15-3水平对乳腺癌骨转移的诊断价值。结果乳腺癌骨转移组血清CA15-3水平高于无骨转移组(P<0.01)。骨转移累及部位数目与CA15-3水平的Spearman相关性分析结果显示两者并无相关性(r=-0.056,P=0.768)。ROC曲线分析结果显示CA15-3血清水平用于判断乳腺癌骨转移有显著意义(P=0.000)。当选CA15-3 24.675 U/mL为诊断界点,灵敏度为91.7%,特异度为93.8%。结论 CA15-3水平可以作为乳腺癌骨转移诊断的初步筛选指标。 Objective To explore the evaluation of carbohydrate antigen 15-3(CA15-3) for bone metastasis of breast cancer.Methods A total of 86 patients with definite histopathology diagnosis of breast cancer and bone metastasis certified by skeletal scinitigraphy and histopathology were included.Site of bone involvement area of bone and the number of area about bone involvement were recorded.According to whether the bone metastasis was existed,86 patients were divided into two groups.Serum levels of CA15-3 were measured by electrochemiluminescence.The correlation between the number of area about bone involvement and the serum levels of CA15-3 was assessed.ROC diagram were used to evaluate the diagnostic value of CA15-3 for bone metastasis of breast cancer.Results The average serum level of CA15-3 in the bone metastasis group was higher than that in the non-bone metastasis group(P〈0.01).The correlation between the number of area about bone involvement and the serum levels of CA15-3 was not statistically significant(r=-0.056,P=0.768).ROC diagram for anticipation of presence of bone metastasis of breast cancer,and it was demonstrated this variable was sufficient for this purpose(P=0.000).When the cut-off point was 24.675 U/mL,the sensitivity and specificity were 91.7% and 93.8%,respectively.Conclusion The measurement of the serum levels of CA15-3 can be used as a preliminary screen to select patients of bone metastasis of breast cancer.
出处 《山东医药》 CAS 2012年第20期13-15,共3页 Shandong Medical Journal
基金 天津市应用基础及前沿技术研究计划(08JCYBJC05500)
关键词 糖类抗原15-3 乳腺肿瘤 骨转移 carbohydrate antigen 15-3 breast neoplasms bone metastasis
  • 相关文献

参考文献9

  • 1Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone me- tastases in breast cancer: techniques and recommendations for diag- nosis [J]. Lancet Oncol, 2009,10(6) :606-614.
  • 2Nicolini A, Carpi A, Ferrari P, et al. Utility of a serum turnout marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations [ J ]. Tumour Biol, 2003,24(6) :275-280.
  • 3del Rocfo Estrada-Srnchez G, Mireles Enrlquez M, Valverde Cas- taneda N. Reliability of CA15-3 in the follow up of female patients with breast carcinoma and bone metastasis [J]. Rev Invest Clin, 2003,55 (4) :412-418.
  • 4Ruibal A, Garrido Pumar M, Arias JI. Preoperative serum CA15-3 and CEA levels and clinical-biological parameters in breast tumors [J]. Rev Esp Med Nuel, 2006,25(3) :180-183.
  • 5Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA15-3 in 362 node-negative breast cancers. An old player for a new game [J]. Cur J Cancer, 2002,38(9) :1181-1188.
  • 6Wojtacki J, Kruszewski WJ, Sliwifiska M, et al. Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases [J]. Przegl Lek, 2001, 58(6) :498-503.
  • 7Giai M, Roagna R, Ponzone R, et al. TPS and CA 15-3 serum val- ues as a guide for treating and monitoring breast cancer patients [ J ]. Anticancer Res, 1996,6 ( 2 ) : 875-881.
  • 8蔡海峰,赵刚,刘远廷.检测血清扩散因子和糖类抗原-153在乳腺癌诊断与治疗中的临床意义[J].中国综合临床,2007,23(4):336-337. 被引量:1
  • 9Di Gioia D, Heinemann V, Nagel D, et al. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC) [ J]. Tumour Bi- ol, 2011,32(4) :777-785.

二级参考文献9

  • 1万文徽,李吉友.肿瘤标志的临床应用[J].中华医学检验杂志,1997,20(1):49-51. 被引量:180
  • 2Nakmura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor [ J]. Nature, 1994,324(6248) :440-443.
  • 3Han ZG. Regulation of motility, invasiveness and growth of lung cancer ceLls by hepatocyte growth factor/scatter factor[ J ]. Surg Res Comn,1996,18(7) :217.
  • 4Jiang WG, HaUett MB, Puntis MCA. Hepatocyte growth factor/scatter factor,liver regeneration and cancer metastasis [ J ]. Br J Surg,1993,80 ( 11 ) :1368-1373.
  • 5Yamashita J, Ogawa M, Yamashita S, ct al. Immunocreative hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [ J]. Cancer Res, 1994,54(7) : 1630-1637.
  • 6Rubin JS, Chan AM, Bottaro DP, et al. A brood-spectrum human lung fibroblast - derived mitogen is a variant of hepatoeyte growth factor[J]. Proc Nail Acad Sci USA,1991,88(2) :415-419.
  • 7Haglund C, Lundin J, Kuusela D, et al. Ca242 anew tumor marker for pancreaticcancer[ J ]. Br J Cancer, 1994,70 (3) :487.
  • 8Essmann-Seboth D,Fuchs I,Jakesz R,et al. CA15-3 in the post operative follow-up of breast cancer patients [ M ]//KlapdorR, eds.Current tumor diagnosis : application, clinical relevance, research,trends. New York : W Zuekschwerdt Verlag, 1994 : 158-159.
  • 9冷建杭.肝细胞生长因子生物学作用研究进展[J].国外医学(生理病理科学与临床分册),2000,20(1):49-51. 被引量:10

同被引文献20

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部